Beginning Next Week: InsideCounsel will become part of Corporate Counsel. Bringing these two industry-leading websites together will now give you comprehensive coverage of the full spectrum of issues affecting today's General Counsel at companies of all sizes. You will continue to receive expert analysis on key issues including corporate litigation, labor developments, tech initiatives and intellectual property, as well as Women, Influence & Power in Law (WIPL) professional development content. Plus we'll be serving all ALM legal publications from one interconnected platform, powered by, giving you easy access to additional relevant content from other InsideCounsel sister publications.

To prevent a disruption in service, you will be automatically redirected to the new site next week. Thank you for being a valued InsideCounsel reader!


More On

FDA-approved surgical mesh faces review

Lawsuits rise against Johnson & Johnson over the product

A panel of Food & Drug Administration (FDA) advisers are meeting to determine whether vaginal mesh is safe and effective. The Johnson & Johnson product is used to support weakened muscles—holding pelvic organs in place.

To date, about 500 suits have been filed against J&J. Plaintiffs claim the mesh causes excruciating pain that is comparable to or worse than childbirth. The product has been used for three decades, primarily to treat hernias, but only recently has its use been expanded to treat pelvic muscle weakness.

"As industry modified surgical mesh for these indications, none of the mesh has been evaluated for clinical data," Herbert Lerner, acting director in the FDA’s device approval center, said at the hearing yesterday.

The FDA had warned in July that there had been a rise in injuries related to the mesh and the device should be reclassified from moderate risk to high risk. The change would require new clinical data.


Cathleen Flahardy

Bio and more articles

Join the Conversation

Advertisement. Closing in 15 seconds.